{"filing":{"accession_number":"0000313143-26-000095","cik":"0000313143","ticker":"HAE","company_name":"HAEMONETICS CORP","form":"8-K","filing_date":"2026-07-28","report_date":"2026-07-24","primary_document":"hae-20260724.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/313143/000031314326000095/hae-20260724.htm"},"events":[{"id":21138,"run_id":19054,"accession_number":"0000313143-26-000095","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Martin Madaus was elected as a director of Haemonetics Corporation, effective July 24, 2026, and appointed to the Audit Committee and Governance and Compliance Committee.","company_name":"HAEMONETICS CORP","ticker":"HAE","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20697,"accession_number":"0000313143-26-000095","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the election of Martin Madaus as a director of Haemonetics Corporation, effective July 24, 2026. The principal action is a person taking a role on the Board, with appointment to the Audit Committee and Governance and Compliance Committee. While Item 5.02(e) also addresses compensation plan amendments (the Amended Plan and ESPP), the core disclosure in subsection (d) centers on the director appointment itself, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:28:43.071329+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":21139,"run_id":19054,"accession_number":"0000313143-26-000095","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Haemonetics held its 2026 annual shareholder meeting on July 24, 2026, with voting results on five proposals: election of eight directors, advisory vote on named executive officer compensation, ratification of Ernst \u0026 Young LLP as auditor, and approval of amendments to the 2019 Long-Term Incentive Compensation Plan and 2007 Employee Stock Purchase Plan.","company_name":"HAEMONETICS CORP","ticker":"HAE","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20698,"accession_number":"0000313143-26-000095","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Item 5.07 discloses the results of the 2026 annual shareholder meeting held July 24, 2026, including voting outcomes on five proposals: election of eight directors, advisory vote on named executive officer compensation, ratification of Ernst \u0026 Young LLP as auditor, approval of amendments to the 2019 Long-Term Incentive Compensation Plan, and approval of amendments to the 2007 Employee Stock Purchase Plan. The filing presents detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:28:43.071329+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20697,"accession_number":"0000313143-26-000095","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the election of Martin Madaus as a director of Haemonetics Corporation, effective July 24, 2026. The principal action is a person taking a role on the Board, with appointment to the Audit Committee and Governance and Compliance Committee. While Item 5.02(e) also addresses compensation plan amendments (the Amended Plan and ESPP), the core disclosure in subsection (d) centers on the director appointment itself, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:28:43.071329+00:00","company_name":"HAEMONETICS CORP","ticker":"HAE","filing_date":"2026-07-28"},{"id":20698,"accession_number":"0000313143-26-000095","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Item 5.07 discloses the results of the 2026 annual shareholder meeting held July 24, 2026, including voting outcomes on five proposals: election of eight directors, advisory vote on named executive officer compensation, ratification of Ernst \u0026 Young LLP as auditor, approval of amendments to the 2019 Long-Term Incentive Compensation Plan, and approval of amendments to the 2007 Employee Stock Purchase Plan. The filing presents detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:28:43.071329+00:00","company_name":"HAEMONETICS CORP","ticker":"HAE","filing_date":"2026-07-28"}]}